VIDEO: Adjuvant capecitabine has role for residual disease after neoadjuvant therapy

SAN ANTONIO – Adjuvant capecitabine improved both disease-free and overall survival in women with HER2-negative breast cancer who had residual disease after neoadjuvant chemotherapy. In an interview, Dr. Masakazu Toi, a professor at Kyoto University Hospital, and founder and senior director of the Japan Breast Cancer Research Group, discusses the phase III CREATE-X trial and its implications for clinical care.

SAN ANTONIO – Adjuvant capecitabine improved both disease-free and overall survival in women with HER2-negative breast cancer who had residual disease after neoadjuvant chemotherapy. In an interview, Dr. Masakazu Toi, a professor at Kyoto University Hospital, and founder and senior director of the Japan Breast Cancer Research Group, discusses the phase III CREATE-X trial and its implications for clinical care.

SAN ANTONIO – Adjuvant capecitabine improved both disease-free and overall survival in women with HER2-negative breast cancer who had residual disease after neoadjuvant chemotherapy. In an interview, Dr. Masakazu Toi, a professor at Kyoto University Hospital, and founder and senior director of the Japan Breast Cancer Research Group, discusses the phase III CREATE-X trial and its implications for clinical care.